1′-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-κB activation

Molecular Cancer Research

Volumn 4, Issue 4, 2006, Pages 275-281

  Ichikawa, Haruyo ^a   Murakami, Akira ^b   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1' ACETOXYCHAVICOL ACETATE; ACETIC ACID DERIVATIVE; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG; 1'-ACETOXYCHAVICOL ACETATE; CARRIER PROTEIN; I KAPPA B KINASE; MEMBRANE PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TERPENE; TNFRSF11A PROTEIN, HUMAN; TNFRSF11A PROTEIN, MOUSE; TNFSF11 PROTEIN, HUMAN; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; ANIMAL; CELL CULTURE; CYTOLOGY; DOWN REGULATION; DRUG ANTAGONISM; METABOLISM; NEOPLASM; OSTEOLYSIS; PHYSIOLOGY;

ANIMALIA; KAEMPFERIA GALANGA; MINK CELL FOCUS-FORMING VIRUS; MURINAE;

ANIMALS; BONE RESORPTION; CARRIER PROTEINS; CELL DIFFERENTIATION; DOWN-REGULATION; HUMANS; I-KAPPA B KINASE; MEMBRANE GLYCOPROTEINS; MICE; MONOCYTES; NEOPLASMS; NF-KAPPA B; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TERPENES; TUMOR CELLS, CULTURED;

EID: 33646144228     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0227     Document Type: Article

References (50)

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
2. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
3. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-602.
4. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4.
5. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
6. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
7. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
8. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38.
9. Xu J, Tan JW, Huang L, et al. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-κB ligand. J Bone Miner Res 2000;15:2178-86.
10. Zhang YH, Heulsmann A, Tondravi MM, et al. Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001;276:563-8.
11. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-5.
12. Galibert L, Tometsko ME, Anderson DM, et al. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily. J Biol Chem 1998;273:34120-7.
13. Darnay BG, Haridas V, Ni J, et al. Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem 1998;273:20551-5.
14. Wada T, Nakashima T, Oliveira-dos-Santos AJ, et al. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat Med 2005;11:394-9.
15. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438-45.
16. Zhang J, Dai J, Yao Z, et al. Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone. Cancer Res 2003;63:7883-90.
17. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004;91:718-29.
18. De Leenheer E, Mueller GS, Vanderkerken K, et al. Evidence of a role for RANKL in the development of myeloma bone disease. Curr Opin Pharmacol 2004;4:340-6.
19. Colucci S, Brunetti G, Rizzi R, et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004;104:3722-30.
20. Granchi D, Amato I, Battistelli L, et al. In vitro blockade of receptor activator of nuclear factor-κB ligand prevents osteoclastogenesis induced by neuroblastoma cells. Int J Cancer 2004;111:829-38.
21. Roato I, Grano M, Brunetti G, et al. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 2005;19:228-30.
22. Bhatia P, Sanders MM, Hansen MF. Expression of receptor activator of nuclear factor-κB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 2005;11:162-5.
23. Zannettino AC, Farrugia AN, To LB, et al. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors. Methods Mol Med 2005;113:245-56.
24. Shibata H, Abe M, Hiura K, et al. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-κB ligand and vascular endothelial growth factor to enhance osteoclastogenesis. Clin Cancer Res 2005;11:6109-15.
25. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-66.
26. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-37.
27. Ichikawa H, Takada Y, Murakami A, et al. Identification of a novel blocker of IκBα kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-κB-regulated gene products. J Immunol 2005;174:7383-92.
28. Ito K, Nakazato T, Xian MJ, et al. 1′-Acetoxychavicol acetate is a novel nuclear factor κB inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res 2005;65:4417-24.
29. 2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J Biol Chem 2005;280:11395-403.
30. Hirotani H, Tuohy NA, Woo JT, et al. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem 2004;279:13984-92.
31. Rothwarf DM, Karin M. The NF-κB activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999;1999:RE1.
32. Chikatsu N, Takeuchi Y, Tamura Y, et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 2000;267:632-7.
33. Hunt NC, Fujikawa Y, Sabokbar A, et al. Cellular mechanisms of bone resorption in breast carcinoma. Br J Cancer 2001;85:78-84.
34. Dai S, Hirayama T, Abbas S, et al. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 2004;279:37219-22.
35. Tada T, Jimi E, Okamoto M, et al. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. Int J Cancer 2005;116:253-62.
36. Wei S, Teitelbaum SL, Wang MW, et al. Receptor activator of nuclear factor-κB ligand activates nuclear factor-κB in osteoclast precursors. Endocrinology 2001;142:1290-5.
37. Uhlik M, Good L, Xiao G, et al. NF-κB-inducing kinase and IκB kinase participate in human T-cell leukemia virus I Tax-mediated NF-κB activation. J Biol Chem 1998;273:21132-6.
38. Iotsova V, Caamano J, Loy J, et al. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 1997;3:1285-9.
39. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
40. Darnay BG, Ni J, Moore PA, et al. Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 1999; 274:7724-31.
41. Yamamoto A, Miyazaki T, Kadono Y, et al. Possible involvement of IκB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor κB ligand. J Bone Miner Res 2002;17:612-21.
42. Boyce BF, Xing L, Franzoso G, et al. Required and nonessential functions of nuclear factor-κB in bone cells. Bone 1999;25:137-9.
43. Franzoso G, Carlson L, Xing L, et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 1997;11:3482-96.
44. Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-80.
45. Jimi E, Akiyama S, Tsurukai T, et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 1999;163:434-42.
46. Xing L, Bushnell TP, Carlson L, et al. NF-κB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 2002;17:1200-10.
47. Chaturvedi MM, Mukhopadhyay A, Aggarwal BB. Assay for redox-sensitive transcription factor. Methods Enzymol 2000;319:585-602.
48. Takada Y, Mukhopadhyay A, Kundu GC, et al. Hydrogen peroxide activates NF-κB through tyrosine phosphorylation of NF-κB and serine phosphorylation of p65: evidence for the involvement of IκBα kinase and Syk protein-tyrosine kinase. J Biol Chem 2003;278:24233-41.
49. Manna SK, Mukhopadhyay A, Aggarwal BB. IFN-α suppresses activation of nuclear transcription factors NF-κB and activator protein 1 and potentiates TNF-induced apoptosis. J Immunol 2000;165:4927-34.
50. Shevde NK, Bendixen AC, Dienger KM, et al. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A 2000;97:7829-34.